# Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

> **NCT01009970** · PHASE2 · UNKNOWN · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 50 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01009970
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2011-05
- **Final completion:** 2012-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009970, "Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01009970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*